UCSF home page | About UCSF | UCSF Medical Center

Skip to TransPortal content

Enlarge Text
Click to increase the text size. Restore Text
Click to restore original text size. Reduce Text
Click to decrease the text size.


Decrease the text size \| Restore text size \| Increase the text size

1-methyl-4-phenylpyridinium (MPP+)

In Vitro Substrates

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Km (μM)	Cell System	Reference
SLC22A1	OCT1	14.6	OCT1-expressing oocytes	Zhang, 1997
SLC22A1	OCT1	6.38	MDCK-OCT1	Tu, 2013
SLC22A1	OCT1	35	HEK293-OCT1	Boxberger, 2014
SLC22A2	OCT2	5.1	CHO-OCT2	Severance, 2017
SLC22A2	OCT2	4.6	CHO-OCT2	Sandoval, 2018

* denotes drugs that can potentially be used for in vivo (clinical) studies of the designated transporter

Transporter	Synonyms	Inhibitor	IC50 (μM)	Substrate used	Cell System	Reference
SLC47A2	MATE2K	1-methyl-4-phenylpyridinium (MPP+)	3.3	1-methyl-4-phenylpyridinium (MPP+)	CHO-MATE2K	Astorga, 2012
SLC22A2	OCT2	1-methyl-4-phenylpyridinium (MPP+)	7	1-methyl-4-phenylpyridinium (MPP+)	CHO-OCT2	Severance, 2017
SLC22A1	OCT1	1-methyl-4-phenylpyridinium (MPP+)	390	Ethidium	CHO-OCT1	Lee, 2009
SLC22A5	OCTN2	1-methyl-4-phenylpyridinium (MPP+)	1700	L-carnitine	BeWo cells expressing OCTN2	Rytting, 2005
SLC22A2	OCT2	1-methyl-4-phenylpyridinium (MPP+)	3	NBD-MTMA	CHO-OCT2	Belzer, 2013

No drug-drug interaction information.